SCHEMBL696316

SCHEMBL696316

CCc1cc(Br)ccc1C(=O)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
CES2 O00748 1/20 0.41
GALR3 O60755 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
PRNP P04156 1/20 0.40
PPARG P37231 1/20 0.40
HIF1A Q16665 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
KDM4E B2RXH2 3/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.39
GLA P06280 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257249 0.85 KDM4E (0.50) CYP1A2CYP2C9CYP2C19PRNPPPARG
SCHEMBL6513432 0.81 HSD17B1 (0.56) ALDH1A1CES2GALR3CYP1A2CYP2C9
SCHEMBL4474491 0.79 ALDH1A1 (0.40) ALDH1A1CES2GALR3CYP1A2CYP2C9
SCHEMBL4446190 0.79 DGAT1 (0.56) CES2GALR3CYP1A2CYP2C9CYP2C19
SCHEMBL167162 0.79 CSNK2A1 (0.41) CES2CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL11444415 0.79 MAPT (0.40) ALDH1A1CES2GALR3CYP1A2CYP2C9
SCHEMBL11444417 0.79 NPSR1 (0.37) ALDH1A1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL14799647 0.79 HSP90AB1 (0.47) ALDH1A1CES2GALR3CYP1A2CYP2C9
SCHEMBL17338793 0.78 PRNP (0.35) ALDH1A1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL24099745 0.78 L3MBTL1 (0.40) ALDH1A1CES2GALR3CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 ALDH1A1 727/4885CES2 2370/4885GALR3 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.